Yuhan Corporation to invest 1.6 billion Won (1.34 million USD) in Yuhan USA U.S. Open Innovation Investment Continues

Yuhan USA strengthens its role as a ‘venture capital’. They purchased 750,000 shares of Processa Pharmaceuticals this year. Yuhan Corporation is spurring overseas open innovation expansion and strengthening its global position by continuously investing in ‘Yuhan USA’, a leading edge for global advancement.  According to industry sources on October 11th, Yuhan Corporation acquired 1.5 million shares by investing 1.667 billion Won (1.4 million […]

Processa Pharmaceuticals’ PCS12852, originally developed by Yuhan Corp, cleared by FDA to Proceed with Ph2a Trial for Gastroparesis

Processa Pharmaceuticals announced that they have been cleared by the FDA to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis. PCS12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist, originally developed by Yuhan Corporation in South Korea, and exclusively licensed to Processa Pharmaceuticals […]

[Job Opening] Associate, Business Operations – San Diego office

Job description Responsibilities: Provide administrative support to include arranging travel plans and meetings; interact and liaise with members of the functional team, management and external clients Perform office duties that include ordering supplies and maintaining an organized filing system of paper and electronic documents File and retrieve corporate records, documents, and reports. Accurately record minutes […]

Yuhan to license out a gastrointestinal drug candidate to Processa for $415 million

Yuhan Corporation entered into a licensing agreement worth up to $415 million with Processa Pharmaceuticals for the development of YH12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID). YH12852 is an agonist that exhibits excellent selectivity to a receptor (5-HT4) that plays an essential role in the regulation […]

[Job Opening] Business Development Manager – San Diego office

Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an outpost of Yuhan’s globalization strategy, Yuhan USA is seeking new opportunities to expand its business domain through searching new drug materials and companies that match with Yuhan’s targeted therapeutic areas […]

Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody

Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for COVID-19 therapy, which they plan to begin testing on humans before the end of this year. According to Yuhan and Abclon, their antibody in a […]

Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation

Yuhan Corporation has in-licensed GI Innovation’s allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation allergy treatment will cover all four major allergic diseases, which are allergic asthma, chronic urticaria, atopic dermatitis, and food allergy. Under this license and co-development […]

Yuhan Corporation to recoup KRW 200 billion investment in five years

Yuhan Corporation’s global R&D and open innovation strategy – in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the pharmaceutical giants – is now reaping its benefits. Yuhan, which formerly led the Korean pharmaceutical industry with its sales force, has transformed itself into an […]